demand for a non-opiod pain med is very high, very large deals for phase I products and companies are happening every day. We will see. They might have to settle for $25MM up front and then $25-50 for moving into phase IIB/III, but there is a lot of money out there chasing these types of compounds. More evidence would help in the up front cash, but should not prohibit a reasonable deal.
Also regarding your recent fixation with dilution, management has a strong personal incentive to boost the share price, not to destroy it with low-priced dilution, debt, converts, warrants. They have plenty of cash for now IMO. More would be better, but not at this price/cost.
and hopefully punish the lying shorts that have not yet exited. 371 first for $50-100MM up front with milestones and 10% royalty with no development costs. That will buy another year+ to prove that either 334 or 811 works and then they partner that one and get a large up front, or acquisition at $5-10+ depending on how strong (results) and how long ARNA holds 334, 371 and 811. That's how the ARNA shareholders win, if we win...Axovant is another wild card and Belviq CVOT could be the icing on the cake (or not).
so, you are providing free tax and investment advice. What are your qualifications?
don't waste your key strokes on these fraudsters, report abuse, ignore, my front page is almost completely empty. Not sure why shorts are so desperate. I guess they are not used to having a CEO completely focused on delivering a higher share price. JL and his over-paid bean counter were their greatest ally.
s3 is boiler plate
no product is going generic before it's even launched you friggin moron
You people have no soul and will pay some day either here, or in hell.
it's too soon/early for that unless JNJ buys the Hep C and they spin out FD, which is essentially what they have already done. The future value depends on FD and Hep C. If either is a winner, shareholders win. If Hep C fails, shareholders will get a final, ST chance to buy more for $4-5. All IMO, not advice I hope they are both winners and we get $40-50 in the next 2 years...
yes, now that they have trimmed the pork, something JL and the worthless BOD should have done 1-2 years ago...
I would not be surprised if the shorts bribed someone to fake report anxiety, or some pretend illness. They will not stop until they're out, or in jail. Even then I'm not sure they would stop.
data are not data is and if you think data are in, how do you know this and are they + or - not that I really think you know...
$30 please, let's get her over $3 or even $2 first then we can think about $4-5 and they will be heroes.
371 partner this year and 334 partner (or acquisition) next year after Phase II data. They can't afford to develop it and they would be too slow and lacking in development talent/experience. This is the ARNA model until acquisition in 1-2 years IMO.
it's somewhat of a #$%$ shoot for retail investors because many biotech leaders are not trust worthy, or not good business people, or in JL's case neither.
In the next 6-12 months we will see if their technology and products work and they can convince a large pharma player to partner, or not. There has never been a better time to find a partner, deals are happening almost daily. ARNA needs evidence to strike a deal and credibility to win over the investment community.
Right now, both are lacking and there in lies the opportunity and the risk.
A few years ago in was a tine $2-3 stock working on rare diseases. Earlier this year it was acquired by Shire for $37.5 or about $6BB, or 4-5x the current valuation of ACHN. "If" FD works ACHN could be worth more. We'll know more in the coming months and years...